

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Senior Editor:** Ulrike Knies-Bamforth**Content Development Manager:** Manpreet Bassan**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

84 Theobald's Road, London, UK WC1X 8RR

Tel: +44 20 7611 4400

Fax: +44 20 7611 4485

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jeff Augen** *TurboWorx, USA***Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Christine DeBouck** *GlaxoSmithKline, USA***Sean Ekins** *ACT LLC and Collaborations in**Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Kevin Fitzgerald** *Bristol Myers-Squibb, USA***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong, Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica,**China***Stephen Naylor** *Predictive Physiology and Medicine Inc., USA***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd. USA***Janice Reichert** *Tufts Center for the Study of Drug Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Tomi Sawyer** *ARIAD Pharmaceuticals, USA***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Nigel Spurr** *GlaxoSmithKline, UK***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute, USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston, USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical School, USA*

DRUG DISCOVERY TODAY

PERSPECTIVE

FEATURE**995 A Sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond***Cele Abad-Zapatero*

MONITOR

1083 Novel compounds directed against the inhibition of protease cascades*Paul Edwards***1085 DIARY****FORTHCOMING ARTICLES****Microfluidics for Drug Discovery and Development: From Target Selection to Product Lifecycle Management***by Lifeng Kang, Bong Geun Chung, Robert Langer and Ali Khademhosseini***Strategic approaches to developing drug treatments for ALS***by Andrea M. Vincent, Stacey A. Sakowski, Adam Schuyler and Eva L. Feldman***Development trends for new cancer therapeutics and vaccines***by Janice M Reichert and Julia B Wenger Bright***Future of Optical Assays for Ion Channel Drug Discovery***by Elena Molokanova and Alex Savchenko***Molecule-Pharmacophore Superpositioning and Pattern Matching in Computational Drug Design***by Gerhard Wolber, Thomas Siedel, Fabian Bendix and Thierry Langer*